med chem

Card Set Information

Author:
tab
ID:
146137
Filename:
med chem
Updated:
2012-04-06 21:13:35
Tags:
med chem quiz
Folders:

Description:
med chem quiz 8
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user tab on FreezingBlue Flashcards. What would you like to do?


  1. bile acid sequestrant used adjuntly to diet and exercise to improve glycemic control in adults with type 2 DM
    colesevelam - welchol
  2. recombinant biotechnology product
    treatment of lower extremity diabetic neuropathic ulcers
    becaplermin - regranex
  3. adjunct to diet and exercise to improve glycemic control in type 2 diabetes only
    dopamine receptor agonist
    taken orally (low doses) within 2 hours of awakening with food
    bromocriptine mesylate - cycloset
  4. DPP-IV inhibitor
    new in 2011
    taken with or without food
    not used in patients with type 1 diabetes or treatment of diabetic ketoacidosis
    90% excreted unchanged
    linagliptin - tradjenta
  5. found in beta-islet cells in pancreas
    acts within a cell in contrast to a receptor
    released along with insulin
    binds directly to a series of GTPase enzymes
    seratonin
  6. sulfonylureas - first gen.
    serum half life - 7 hours
    active metabolites
    tolazamide - tolinase
  7. sulfonylureas - first gen.
    half life - 4.5-6.5 hours
    NO active metablolites
    tolbutamide - orinase
  8. sulfonylureas - first gen.
    half life - 36 hours
    active metabolites
    chlorproppamide - diabinese
  9. sulfonylureas - first gen.
    half life - 6-8 hours
    acitve metabolites
    acetohexamide - dymelor
  10. sulfonylureas - second gen
    half life - 2-4 hours
    NO active metabolites
    glipizide - glucotrol
  11. sulfonylureas - second gen.
    nonmicronized half life - 10 hours
    weakly active metabolites
    micronized half life - 4 hours
    weakly active metabolites
    glyburide (glibenclamide) - DiaBeta, micronase, glynase prestab
  12. sulfonylureas - third gen.
    half life 9 hours
    active metabolites
    causes tranlocation of GLUT-4 to cell surface
    may bind to a different protein than beta-islet cell
    glimepiride - amaryl
  13. thiazolidinediones
    type 2 diabetes alone or with sulfonylurea or insulin
    only work in the presence of insulin
    increase the activity of PPAR -gamma
    metabolized by CYP2C8 and some CYP2C9
    rosiglitazone maleate - avandia
  14. thiazolidinedionestype 2 diabetes alone or with sulfonylurea or insulinonly work in the presence of insulinincrease the activity of PPAR -gamma
    metabolized by CYP3A4
    decreases the efficacy of OC's
    monitor ALT for hepatotoxicity
    pioglitazone HCL - actos
  15. non-sulfonylurea analog of glyburide
    binds, and blocks an ATP-ase sensitve K+ channel.
    metabolized by CYP3A4
    take preprandially
    repaglinide - prandlin
  16. decrease hepatic gluconeogenesis and intestinal glucose absorption
    increase peripheral tisssue insulin sensitivity
    does not cause insulin release in the pancrease
    half life - 1.3-4.5 hours
    metformin HCL - glucophage
  17. unrelated to sulfonylureas
    stimulates insulin release in the pancreas
    98% albumin binding
    CYP2C9 metabolism (70%)
    CYP3A4 metabloism (30%)
    nateglinide - starlix
  18. alpha-glucosidase inhibitor
    decrease carbohydrate absorption
    amino group prevents protonation of glycosidic bonds in the saccharides
    tell patients take drug with the first bite of meals tid
    minimal systemic absorption
    acarbose - precose
  19. alpha-glucosidase inhibitordecrease carbohydrate absorptionamino group prevents protonation of glycosidic bonds in the saccharidestell patients take drug with the first bite of meals tid
    rapid and complete systemic absorption
    miglitol - glyset
  20. combination products for type 2 diabetes (6)
    • glipizide and metformin HCL - metaglip
    • rosiglitazone maleate and metformin - avandamet
    • glyburide and metformin HCL - glucovnace
    • rosiglitazone maleate and glimepiride - avandaryl
    • repaglinide and metformin - prandimet
  21. rapid acting product recombinant site directed mutation human insulin produced in E. Coli
    lysine replaces asparagine at position 3 and glutamic acid replaces lysine at postion 29
    insulin glulisine - apidra
  22. long acting 24 hour product reconbinant site directed mutation human insulin produced in saccharoyces cerevisiae followed by chemical modification with a fatty acid
    98% bound to plasma albumin
    threonine at B30 deleted and a C14 fatty acid chain has been attached to the B29 amino acid lysine
    insulin detemir - levemir
  23. forms microprecipitates in subcutaneous tissue prolinging diration from 18-26 hours
    recombinant/chemically modified insulins
    insulin glargine - lantus
  24. rapid acting 3-5 hour duration
    take 5-10 minutes before meals
    recombinant/chemically modified insulin
    insulin aspart - novolog
  25. rapid acting 3-5 hour durationt
    take 15 minutes before meals or immediately after eating
    insulin lispro - humalog
  26. incretin memetic or glucagon-like peptide-1 receptor agonist that binds the GLP-1 receptor on beta islet cells causing insulin synthesis and excretion
    exenatide - byetta
  27. synthetic analog of human amylin
    pramlintide acetate-symlin
  28. combination product for type 2 diabetes
    two modes of action - directly targets insulin resistance and acts primarily to increase the amount of insulin produced by the pancreas
    pioglitazone HCL and glimepiride - duetact
  29. inhaled insulin for diabetes mellitus
    rapid acting insulin
    patient variability on correct use and dose left in blister packages = not marketed
    exubera
  30. peptide hormones released from the gut in response to the ingestion of carbohydrates
    incretins
  31. incretin memetic or glucagon like peptide-1 receptor agonist as an adjunct to diet and excercise
    inject sub Q qd any time of the day independent of meals
    black box warning - risk of thyroid C-cell tumors
    victoza - liraglutide
  32. monotherapy for type 2 diabetes, NOT for 1
    combination therapy with metformin and thiazolidines
    with or without food
    substrate of p-glycoprotein
    sitagliptin - januvia
  33. DPP-4 inhibitor
    metabolism - CYP3A4/5 to active metabolite
    AR - decreased lymphocyte count, hypoglycemia, uticaria, acute pancreatitis, and headaches
    saxagliptin - onglyza
  34. combo products with sitagliptin (2)
    • with metformin - janumet
    • with simvastatin - juvisyns

What would you like to do?

Home > Flashcards > Print Preview